$VVOS
Vivos Therapeutics, Inc. Stock $vvos

$vvos Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045888 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$3.860M
YoY Change		16.93%
Cost Of Revenue		$1.526M
YoY Change		1426.0%
Gross Profit		$2.334M
YoY Change		22.97%
Gross Profit Margin		60.47%
Selling, General & Admin		$4.833M
YoY Change		-7.71%
% of Gross Profit		207.07%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$100.0K
YoY Change		-50.0%
% of Gross Profit		4.28%
Operating Expenses		$4.979M
YoY Change		-7.57%
Operating Profit		-$2.645M
YoY Change		-24.19%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$18.00K
YoY Change		-66.04%
Pretax Income		-$2.616M
YoY Change		25.17%
Income Tax
% Of Pretax Income
Net Earnings		-$2.616M
YoY Change		24.99%
Net Earnings / Revenue		-67.77%
Basic Earnings Per Share		-$0.40
Diluted Earnings Per Share		-$0.40
COMMON SHARES
Basic Shares Outstanding	4.835M shares	3.401M shares
Diluted Shares Outstanding		6.615M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$6.311M
YoY Change		537.47%
Cash & Equivalents		$6.300M
Short-Term Investments
Other Short-Term Assets		$634.0K
YoY Change		-17.66%
Inventory
Prepaid Expenses
Receivables		$454.0K
Other Receivables		$0.00
Total Short-Term Assets		$7.399M
YoY Change		272.75%
LONG-TERM ASSETS
Property, Plant & Equipment		$3.317M
YoY Change		1.04%
Goodwill		$2.843M
YoY Change		0.0%
Intangibles		$383.0K
YoY Change		-11.55%
Long-Term Investments
YoY Change
Other Assets		$276.0K
YoY Change		-10.97%
Total Long-Term Assets		$7.948M
YoY Change		-4.61%
TOTAL ASSETS
Total Short-Term Assets		$7.399M
Total Long-Term Assets		$7.948M
Total Assets		$15.35M
YoY Change		48.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.075M
YoY Change		-29.65%
Accrued Expenses		$2.054M
YoY Change		6.87%
Deferred Revenue		$1.313M
YoY Change		-44.67%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$5.126M
YoY Change		-28.48%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$2.556M
YoY Change		-17.55%
Total Long-Term Liabilities		$2.556M
YoY Change		-17.55%
TOTAL LIABILITIES
Total Short-Term Liabilities		$5.126M
Total Long-Term Liabilities		$2.556M
Total Liabilities		$7.700M
YoY Change		-25.24%
SHAREHOLDERS EQUITY
Retained Earnings		-$101.4M
YoY Change		14.19%
Common Stock		$0.00
YoY Change		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$7.665M
YoY Change
Total Liabilities & Shareholders Equity		$15.35M
YoY Change		48.75%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$2.616M
YoY Change		24.99%
Depreciation, Depletion And Amortization		$100.0K
YoY Change		-50.0%
Cash From Operating Activities		-$4.187M
YoY Change		49.54%
INVESTING ACTIVITIES
Capital Expenditures		$192.0K
YoY Change		20.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$192.0K
YoY Change		20.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.787M
YoY Change
NET CHANGE
Cash From Operating Activities		-4.187M
Cash From Investing Activities		-192.0K
Cash From Financing Activities		3.787M
Net Change In Cash		-592.0K
YoY Change		-80.0%
FREE CASH FLOW
Cash From Operating Activities		-$4.187M
Capital Expenditures		$192.0K
Free Cash Flow		-$4.379M
YoY Change		47.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	4371000	usd
	us-gaap	Gross Profit GrossProfit	6922000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001716166
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	us-gaap	Common Stock Value CommonStockValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39796
	dei	Entity Registrant Name EntityRegistrantName	Vivos Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3224056
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7921 Southpark Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	Littleton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80120
	dei	City Area Code CityAreaCode	(844)
	dei	Local Phone Number LocalPhoneNumber	672-4357
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	VVOS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4835300	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6311000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	454000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	634000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	7399000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	2843000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1129000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	383000	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	276000	usd
CY2024Q3	us-gaap	Assets Assets	15347000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1075000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2054000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	199000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5126000	usd
CY2024Q3	VVOS	Employee Retention Credit Liability EmployeeRetentionCreditLiability	1220000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1158000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	7682000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109025000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101360000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	7665000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15347000	usd
CY2024Q3	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
CY2023Q3	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3317000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1313000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	178000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3860000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3301000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11333000	usd
CY2023Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1554000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	4411000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	2334000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1747000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4487000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4596000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13531000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	346000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	641000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1319000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	150000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	437000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	4979000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	5387000	usd
	us-gaap	Operating Expenses OperatingExpenses	15287000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2645000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3640000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8365000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-53000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	usd
CY2024Q3	us-gaap	Other Income OtherIncome	47000	usd
	us-gaap	Other Income OtherIncome	98000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2616000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2093000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8309000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2616000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2093000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8309000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6615320	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1197258	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.75
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q3	us-gaap	Other Income OtherIncome		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2024Q2	VVOS	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
	VVOS	Increase Decrease In Employees Retention Credit Liability IncreaseDecreaseInEmployeesRetentionCreditLiability		usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	VVOS	Fair Value Of Warrants Issued In Asset Purchase FairValueOfWarrantsIssuedInAssetPurchase		usd
	VVOS	Fair Value Of Warrants Issued In Private Placement FairValueOfWarrantsIssuedInPrivatePlacement		usd
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1643000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	262000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	250000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	202000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	616000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2461000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3314000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1385000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	420000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	307000	usd
CY2023Q4	us-gaap	Assets Assets	10730000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2145000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2334000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2138000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	474000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	198000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7289000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	289000	usd
CY2023Q4	VVOS	Employee Retention Credit Liability EmployeeRetentionCreditLiability	1220000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1521000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10319000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4765300	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4765300	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1833877	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1833877	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93462000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93051000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	411000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10730000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10553000	usd
CY2024Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1526000	usd
	us-gaap	Gross Profit GrossProfit	6182000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17012000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1861000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	146000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	472000	usd
	us-gaap	Operating Expenses OperatingExpenses	19345000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13163000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-198000	usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue	6453000	usd
CY2023Q3	VVOS	Net Of Warrant Liability Issuance Costs NetOfWarrantLiabilityIssuanceCosts	645000	usd
	VVOS	Net Of Warrant Liability Issuance Costs NetOfWarrantLiabilityIssuanceCosts	645000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1600000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10362000	usd
	us-gaap	Other Income OtherIncome	128000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9324000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9324000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.09
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6615320	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6615320	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1197258	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1197258	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4282210	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4282210	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1152607	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1152607	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4801000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	116000	usd
CY2023Q1	VVOS	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2848000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	625000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	306000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1703000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6993000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	182000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	459000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5528000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2106000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	156000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	189000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2093000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	46000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	411000	usd
CY2024Q1	VVOS	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3635000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	293000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3763000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	582000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7400000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	14000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	270000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1930000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6347000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6347000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3786000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	142000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2616000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	7665000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	7665000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8309000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9324000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	705000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	954000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	437000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	472000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	11000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	26000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	651000	usd
	VVOS	Net Of Warrant Liability Issuance Costs NetOfWarrantLiabilityIssuanceCosts	645000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	10362000	usd
	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue	6453000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	252000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-229000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-95000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-81000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-679000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-44000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-81000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1070000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	118000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-293000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	42000	usd
	VVOS	Increase Decrease In Employees Retention Credit Liability IncreaseDecreaseInEmployeesRetentionCreditLiability	1220000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	94000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-935000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-424000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9751000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9198000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	403000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	638000	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	50000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-403000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-688000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4296000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7500000	usd
	VVOS	Proceeds From Exercise Of Prefunded Warrants ProceedsFromExerciseOfPrefundedWarrants	3941000	usd
	VVOS	Proceeds From Exercise Of Prefunded Warrants ProceedsFromExerciseOfPrefundedWarrants	8000000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	915000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	645000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14822000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7355000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4668000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2531000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1643000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3519000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6311000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	988000	usd
	us-gaap	Interest Paid Net InterestPaidNet	7000	usd
	VVOS	Fair Value Of Warrants Issued In Asset Purchase FairValueOfWarrantsIssuedInAssetPurchase	116000	usd
	VVOS	Fair Value Of Warrants Issued In Private Placement FairValueOfWarrantsIssuedInPrivatePlacement	262000	usd
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	1-for-25
	VVOS	Percentage Of Revenue PercentageOfRevenue	0.80	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zvCdbvJNXFc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zpOYgrR7VmZe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, determining customer life and breakage related to recognizing revenue for VIP contracts, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in asset acquisitions; valuation assumptions for stock options, warrants, warrant liabilities and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; and the evaluation and measurement of contingencies. The Company believes it has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2024Q3	VVOS	Gross Receipt Percentage GrossReceiptPercentage	0.50	pure
	VVOS	Employee Retain Description EmployeeRetainDescription	Healthcare plan expenses were not included in the analysis, although they are eligible if an employee has paid health insurance through their paycheck. Section 2301(c)(5)(B) of the CARES Act provides that “wages” include amounts paid by an eligible employer to provide and maintain a group health plan (as defined in section 5000(b)(1) of the Code), but only to the extent that the amounts are excluded from the gross income of employees by reason of section 106(a) of the Code. The Company pays the first $500 of healthcare insurance for each employee, which generally covers the monthly cost of their insurance. Because of this, the Company conservatively did not include any of the cost of insurance in its analysis. Additionally, PPP loan amounts were deducted from the amount of total wages paid before calculating the qualified ERTC wages. The Company applied for the ERTC using Vivos Therapeutics Inc.’s payroll, which covers 95% of its employees.
	VVOS	Eligible Tax Credit Description EligibleTaxCreditDescription	As indicated above, for 2020, companies were eligible for a credit equal to 50 percent of the first ten thousand dollars ($10,000) of qualified wages paid per employee in the aggregate of each eligible quarter. Therefore, the maximum ERTC for the Company for 2020 is five thousand dollars ($5,000) per employee. For the second and fourth quarters of 2020, the total eligible credit was limited to approximately $0.5 million.
CY2024Q3	VVOS	Credit Percentage CreditPercentage	0.70	pure
CY2024Q3	VVOS	Credit Limit CreditLimit	700000	usd
CY2024Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1200000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1200000	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
	us-gaap	Net Income Loss NetIncomeLoss	-8300000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9300000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9200000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	7700000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6300000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3860000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3301000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11333000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10553000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3038000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3038000	usd
CY2024Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	855000	usd
CY2023Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1255000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-962000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1396000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2931000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2897000	usd
CY2024Q2	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	411000	usd
CY2023Q2	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	794000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1195000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1068000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2147000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2623000	usd
CY2024Q3	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	275000	usd
CY2023Q3	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1046000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-931000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1056000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1491000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1300000	usd
CY2024Q3	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	500000	usd
CY2023Q3	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	300000	usd
	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	1500000	usd
	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	400000	usd
CY2023Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	200000	usd
CY2024Q3	us-gaap	Receivables From Customers ReceivablesFromCustomers	500000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	300000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	300000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6043000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5640000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2726000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2326000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3317000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3314000	usd
CY2024Q3	us-gaap	Area Of Land AreaOfLand	15000	sqft
CY2024Q3	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	400000	usd
	us-gaap	Depreciation Depreciation	400000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	2800000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2800000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	2843000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2659000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2659000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2276000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2239000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	383000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	420000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	13000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	50000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	35000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	29000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	29000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	227000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	383000	usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1211000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1498000	usd
CY2024Q3	VVOS	Accrued Legal And Other AccruedLegalAndOther	808000	usd
CY2023Q4	VVOS	Accrued Legal And Other AccruedLegalAndOther	798000	usd
CY2024Q3	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	35000	usd
CY2023Q4	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	38000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2054000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2334000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	10000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	200000	usd
CY2023Q1	us-gaap	Cash Cash	200000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.25
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	1-for-25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	105000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	16000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.38
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	4036	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	24000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	700000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000000.0	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2821000	shares
CY2023Q4	VVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	13.15
CY2023	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1394000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	24000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9244000	shares
CY2024Q3	VVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.98
	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2024Q3	VVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	9095000	shares
CY2024Q3	VVOS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	2.90
	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q3	VVOS	Warrants And Rights Exercisable WarrantsAndRightsExercisable	0	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2616000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2093000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8309000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9324000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2616000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2093000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8309000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9324000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6615320	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1197258	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4282210	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4282210	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1152607	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1152607	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.09
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9472000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	633000	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6300000	usd

Files In Submission

Name	View Source	Status
vvos-20240930_cal.xml	Edgar Link	unprocessable
0001493152-24-045888-index-headers.html	Edgar Link	pending
0001493152-24-045888-index.html	Edgar Link	pending
0001493152-24-045888.txt	Edgar Link	pending
0001493152-24-045888-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vvos-20240930.xsd	Edgar Link	pending
vvos-20240930_def.xml	Edgar Link	unprocessable
vvos-20240930_lab.xml	Edgar Link	unprocessable
vvos-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VVOS
Vivos Therapeutics, Inc. Stock $vvos

2024 Q4 Form 10-Q Financial Statement

#000149315224045888 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS Vivos Therapeutics, Inc. Stock $vvos

2024 Q4 Form 10-Q Financial Statement

#000149315224045888 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS
Vivos Therapeutics, Inc. Stock $vvos